US medtech, biotech companies still concerned with revised patent reform bill - update
This article was originally published in RAJ Devices
Legislation to reform US patent law has been revised and reintroduced in the House of Representatives and the Senate1,2. The Patent Reform Act of 2009 continues to draw stiff opposition from the medtech, biotech and pharmaceutical industry associations, despite attempts by lawmakers to address their concerns and make improvements to the previous version of the act that was introduced in the previous Congress.
You may also be interested in...
While inspection interviews can be stressful for drug firms, a Dutch pharmacovigilance inspector reassures companies that any responses made during the process cannot undo any good work they have already done. And they can also correct any wrong answers later on.
The Saudi Food & Drug Authority looks at the number of individual case safety reports (ICSRs) submitted by a company, among other risk-based factors, when drawing up its list for routine pharmacovigilance inspections.
Based on its experience of reviewing tools used by companies for additional risk minimization, the European Medicines Agency is planning to update its guidance on this topic with more information on how these tools can be better employed.